Narsoplimab
未知生产厂商
Narsoplimab is an anti-MASP-2 antibody currently being investigated for use in transplant-associated thrombotic microangiopathies and IgA nephropathy.
Narsoplimab is an anti-MASP-2 antibody currently being investigated for use in transplant-associated thrombotic microangiopathies and IgA nephropathy.
Transplant-associated thrombotic microangiopathy (TA-TMA) has complex underlying pathophysiology but generally involves complement activation associated with endothelial injury, microthrombus development, and downstream organ dysfunction. Studies have demonstrated a role for the alternative and lectin complement pathways in TMA. Within the lectin pathway, considerable interest has fallen on the effector protein mannan-associated lectin-binding serine protease-2 (MASP-2), which cleaves C4 and C2 to form the C3 convertase C4bC2a. Narsoplimab, a human IgG4λ anti-MASP-2 antibody, appears effective in limiting lectin pathway-associated microvascular activation/injury in TA-TMA, presumably by directly inhibiting the formation of C4bC2a.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
